Get In-depth Biotech Coverage with Timmerman Report.
7
Apr
2026
Computation & Culture For Drug Discovery: Abbas Kazimi on The Long Run
Abbas Kazimi is today’s guest on The Long Run.
Abbas is the CEO of Boston-based Nimbus Therapeutics. It’s a privately held company that discovers and develops oral small molecule drugs. It does this through a combination of computational chemistry, medicinal chemistry, AI, and the combined effort of a small group of talented and hardworking people.

Abbas Kazimi, CEO, Nimbus Therapeutics
Nimbus is probably best known for the discovery of zasocitinib, a Tyk2 inhibitor for psoriasis, and other autoimmune diseases. It sold that drug to Takeda Pharmaceuticals in late 2022 for $4 billion upfront and $2 billion in milestones. That deal rewarded employees, and investors, and allowed the Nimbus team to stay in place and keep working on the next big thing. Takeda is putting a lot of horsepower behind that drug, and its Phase III results suggest it will be a multi-billion blockbuster.
The Nimbus team of small molecule drug hunters is now back doing what it does, working on a couple of internal drug candidates in the early stages of development. One is a cancer drug candidate aimed at the Werner syndrome helicase (WRN) enzyme, and a Salt-Inducible Kinase 2 or SIK2 inhibitor for immune disorders. It also has a collaboration with Eli Lilly to work on small molecules for metabolic disorders, including the biggest market opportunity of them all — obesity.
Abbas joined Nimbus back in 2014 to do strategy and business development. He worked his way up to chief business officer and then became CEO in March 2025. He has helped raise over $630 million in equity financing and led corporate and business development transactions totaling over $8 billion – including that signature deal with Takeda on the Tyk2 inhibitor.
There are elements of the classic immigrant story that run though Abbas’ life. Abbas is brilliant, humble and obviously driven by the industry’s mission to help people who are suffering. He’s someone who embodies what I think of as one of the industry’s simple truths and yet is often overlooked. Success requires both advanced technology and great people working together.
Before we get started, a word from the sponsor of the show.

I want to draw your attention to a live webinar that Alphasense are hosting on Apr 9 – AI in Drug Development 2026: The Shift to Execution
In this live webinar, Sara Mallatt, AlphaSense’s Director of Healthcare Research and Dr. Paul Agapow, former Director of Data Science at GSK, will explore how AI is transforming medicine. As the first wave of AI-designed drugs move into advanced clinical trials, they will discuss whether AI is on track to make drug development faster, cheaper, and more successful.
Register now to save your seat.

Bioanalysis should not rely on which scientists at the CRO you get. These are assays, not consulting. Your results should be the same, regardless of who does the work.
“We love working with our CRO… when we get the right PI” is a red flag, not a compliment. And if the quality of your bioanalysis depends on which principal investigator happens to be assigned to your study, you don’t have a CRO partnership, you have a lottery ticket.
Dash was built around automation and standardized workflows specifically to eliminate that variability. Every study gets the same rigor and the same rapid turnaround, days not weeks, across ELISA/MSD, LC-MS, and PCR. GLP-compliant, transparent pricing, guaranteed outcomes.
You shouldn’t have to ask who’s running your study. You should just get great data.
Visit www.dash.bio
Now please enjoy this conversation with Abbas Kazimi on The Long Run.































